Phase 1b/2 trial of the superoxide dismutase mimetic GC4419 to reduce chemoradiotherapy-induced oral mucositis in patients with oral cavity or oropharyngeal carcinoma
Galera Therapeutics has completed a merger with Obsidian Therapeutics. Visit www.obsidiantx.com to learn more.